Jin Lei, founder of Genesci Pharmaceutical, stated at a J.P. Morgan summit that AI will revolutionize traditional pharmaceutical development. Genesci has leveraged AI to design innovative enzymes that overcome drug resistance, with one product for bacterial vaginosis entering Phase I clinical trials. The company has seen a 50% reduction in early research cycles and a 33% decrease in process optimization costs due to AI integration. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT AI integration is accelerating drug discovery and reducing costs, potentially leading to faster development of new treatments.
RANK_REASON The cluster discusses a founder's opinion on AI's impact on pharmaceuticals and mentions a product in early clinical trials, fitting commentary on industry trends.